Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03690011 |
Recruitment Status :
Recruiting
First Posted : October 1, 2018
Last Update Posted : April 12, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Patients eligible for this study have a type of blood cancer called T-cell lymphoma (lymph gland cancer).
The body has different ways of fighting infection and disease. This study combines two different ways of fighting disease with antibodies and T cells. Antibodies are types of proteins that protect the body from bacterial and other diseases. T cells, or T lymphocytes, are special infection-fighting blood cells that can kill other cells including tumor cells. Both antibodies and T cells have been used to treat cancer; they have shown promise, but have not been strong enough to cure most patients.
T cells can kill tumor cells but there normally are not enough of them to kill all the tumor cells. Some researchers have taken T cells from a person's blood, grown more of them in the laboratory and then given them back to the person.
The antibody used in this study is called anti-CD7. This antibody sticks to T-cell lymphoma cells because of a substance on the outside of these cells called CD7. CD7 antibodies have been used to treat people with T-cell lymphoma. For this study, anti-CD7 has been changed so that instead of floating free in the blood it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor.
In the laboratory, investigators have also found that T cells work better if they also add proteins that stimulate T cells, such as one called CD28. Adding the CD28 makes the cells grow better and last longer in the body, thus giving the cells a better chance of killing the leukemia or lymphoma cells.
In this study, investigators attach the CD7 chimeric receptor with CD28 added to it to T cells. Investigators will then test how long the cells last. These CD7 chimeric receptor T cells with CD28 are investigational products not approved by the Food and Drug Administration.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
T-cell Acute Lymphoblastic Lymphoma T-non-Hodgkin Lymphoma | Genetic: CD7.CAR/28zeta CAR T cells | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 21 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Cell Therapy for High Risk T-cell Malignancies Using CD7-Specific CAR Expressed on Non-Edited T Cells (CRIMSON-NE) |
Actual Study Start Date : | August 2, 2021 |
Estimated Primary Completion Date : | May 1, 2025 |
Estimated Study Completion Date : | May 1, 2040 |
Arm | Intervention/treatment |
---|---|
Experimental: CD7.CAR/28zeta CAR T Cells
Three dose levels will be evaluated. The T cells will be administered following lymphodepleting chemotherapy with cyclophosphamide and fludarabine.
|
Genetic: CD7.CAR/28zeta CAR T cells
Three dose levels will be evaluated:
|
- Number of patients with dose limiting toxicity [ Time Frame: 4 weeks ]To evaluate the safety of escalating doses of autologous peripheral blood T lymphocytes (ATLs) genetically modified to express chimeric antigen receptors (CAR) targeting the CD7 molecule (CD7.CAR) in combination with lymphodepletion in patients with relapsed/refractory T-cell malignancies.
- Overall Response Rate [ Time Frame: 4 weeks ]To measure the anti-tumor effects of CD7.CAR-ATLs in patients with T-cell leukemia or lymphoma.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 75 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Procurement Inclusion Criteria:
Referred patients will initially be consented for procurement of blood for generation of the transduced ATL. Eligibility criteria at this stage include:
1. Diagnosis of recurrent or refractory T-cell acute lymphoblastic lymphoma (T-LLy), or T-non-Hodgkin lymphoma (T-NHL, including Angioimmunoblastic T-cell lymphoma (AITL), Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), Peripheral T-cell lymphoma (PTCL) NOS, Anaplastic large cell lymphoma (ALCL), Adult T-cell leukemia/lymphoma, T cell prolymphocytic leukemia with symptomatic disease, Extranodal NK/T cell lymphoma, Mycosis fungoides/ Sezary Syndrome Stage IIB or higher) or other cutaneous T-cell lymphomas
AND
- suitable for allogeneic hematopoietic stem cell transplant (HSCT)
- with a suitable donor identified by a FACT accredited transplant center
- willing to proceed to transplant if the CD7.CAR treatment induces complete remission and the patient/donor remain suitable candidates
Using NMDP donor assessment criteria, suitability is defined as "during the search process, a donor is medically fit to proceed to the next step- whether high-resolution or confirmatory HLA testing OR donor work-up." Documentation of suitability (including above criteria) will be confirmed by the investigator prior to treatment.
-
For T-NHL subjects, eligibility will be confined to disease stages where allogeneic HSCT is indicated.
2. CD7-positive tumor (≥20% CD7 positive blasts by flow cytometry or immunohistochemistry (tissue) assessed by a CLIA certified Flow Cytometry/Pathology laboratory).
3. Age </=75 years old.. NOTE: The first three (3) patients treated on the study must be adults (>/=18 yrs of age).
4. Hgb ≥ 7.0 (can be transfused)
5. Life expectancy greater than 12 weeks
6. If pheresis required to collect blood:
- Cr < 1.5 upper limit normal
- AST < 5 × upper limit normal
-
PT and APTT <1.5 × upper limit normal
7. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
Procurement Exclusion Criteria:
- Active infection requiring antibiotics.
- Active infection with HIV
- History of other cancer (except non-melanoma skin cancer or in situ breast cancer or cervix cancer) unless the tumor was successfully treated with curative intent at least 2 years before trial entry.
Treatment Inclusion Criteria:
1. Diagnosis of recurrent or refractory T-cell acute lymphoblastic lymphoma (T-LLy), or T-non-Hodgkin lymphoma (T-NHL, including Angioimmunoblastic T-cell lymphoma (AITL), Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), Peripheral T-cell lymphoma (PTCL) NOS, Anaplastic large cell lymphoma (ALCL), Adult T-cell leukemia/lymphoma, T cell prolymphocytic leukemia with symptomatic disease, Extranodal NK/T cell lymphoma, Mycosis fungoides/ Sezary Syndrome Stage IIB or higher) or other cutaneous T-cell lymphomas
AND
1) suitable for allogeneic hematopoietic stem cell transplant (HSCT) 2) with a suitable donor identified by a FACT accredited transplant center 3) willing to proceed to transplant if the CD7.CAR treatment induces complete remission and the patient/donor remain suitable candidates
Using NMDP donor assessment criteria, suitability is defined as "during the search process, a donor is medically fit to proceed to the next step- whether high-resolution or confirmatory HLA testing OR donor work-up." Documentation of suitability (including above criteria) will be confirmed by the investigator prior to treatment.
-
For T-NHL subjects, eligibility will be confined to disease stages where allogeneic HSCT is indicated.
2. CD7-positive tumor (≥20% CD7+ blasts by flow cytometry or immunohistochemistry (tissue) assessed in a CLIA certified Flow Cytometry/Pathology laboratory.
3. Age </=75 years old. NOTE: The first three (3) patients treated on the study must be adults (>/=18 yrs of age).
4. Bilirubin less than 3 times the upper limit of normal.
5. AST less than 5 times the upper limit of normal.
6. Estimated GFR ≥ 50 mL/min.
7. Pulse oximetry of > 90% on room air
8. Karnofsky or Lansky score of ≥ 60.
9. Recovered from acute toxic effects of prior chemotherapy at least one week before entering this study.
10. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.
11. Informed consent explained to, understood by, and signed by patient/guardian. Patient/guardian given copy of informed consent.
Treatment Exclusion Criteria:
- Currently receiving any investigational agents or having received any tumor vaccines within the previous 6 weeks.
- History of hypersensitivity reactions to murine protein-containing products.
- Pregnant or lactating.
- Tumor in a location where enlargement could cause airway obstruction (per investigator discretion).
- Clinically significant viral infection or uncontrolled viral reactivation of EBV, CMV, Adv, BK-virus, or HHV-6.
- Any of the following cardiac criteria: Atrial fibrillation/flutter; Myocardial infarction within the last 12 months; Prolonged QT syndrome or secondary prolonged QT, per investigator discretion. Cardiac echocardiography with LVSF<30% or LVEF<50%; or clinically significant pericardial effusion. Cardiac dysfunction NYHA III or IV (Confirmation of absence of these conditions on echocardiogram within 12 months of treatment).
- CNS abnormalities: Presence of CNS-3 disease defined as detectable cerebrospinal blast cells in a sample of CSF with ≥ 5 WBCs per mm3 (unless negative by the Steinherz/Bleyer algorithm); Presence of any CNS disorder such as an uncontrolled seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03690011
Contact: LaQuisa Hill, MD | 713-441-1450 | LaQuisa.Hill@bcm.edu | |
Contact: Martha Arredondo | 832-824-1201 | Martha.Arredondo@bcm.edu |
United States, Texas | |
Houston Methodist Hospital | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: LaQuisa HIll, MD 832-824-4670 LaQuisa.Hill@bcm.edu | |
Texas Children's Hospital | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Rayne Rouce, MD 832-824-4716 rhrouce@txch.org |
Principal Investigator: | Rayne Rouce, MD | Pediatrics, Baylor College of Medicine | |
Principal Investigator: | LaQuisa Hill, MD | Baylor College of Medicine | |
Principal Investigator: | Maksim Mamonkin, PhD | Baylor College of Medicine |
Responsible Party: | LaQuisa Hill, Assistant Professor, Baylor College of Medicine |
ClinicalTrials.gov Identifier: | NCT03690011 |
Other Study ID Numbers: |
H-43761 - CRIMSON NE |
First Posted: | October 1, 2018 Key Record Dates |
Last Update Posted: | April 12, 2024 |
Last Verified: | April 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Autologous CAR T cells T-cell acute lymphoblastic lymphoma T-non-Hodgkin lymphoma |
Lymphoma Lymphoma, Non-Hodgkin Precursor Cell Lymphoblastic Leukemia-Lymphoma Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders |
Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Leukemia, Lymphoid Leukemia Hematologic Diseases |